1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Viscosupplementation - South America Analysis and Market Forecasts

Viscosupplementation - South America Analysis and Market Forecasts

Summary

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade. Going forward, palliative pain treatments are likely to continue to fare well as healthcare reform kicks in and lag times for knee replacement become the norm.

The increasing prevalence of OA and the lower cost of prescribing viscosupplementation compared with knee replacement surgery have prompted the medical community to take a closer look at this therapy. However, there is a growing concern among physicians that the updated American Academy of Orthopaedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will result in increased insurance denials for viscosupplementation. Moving forward, industry consolidation and intense competition in the viscosupplementation arena will cause increasing numbers of companies to augment their research efforts to differentiate their products from the lower-end competitors. The motivation to incorporate the favorable properties of different agents into a more effective viscosupplementation product has led to the manipulation and development of next-generation HA formulations consisting of not only HAs, but also pharmaceuticals, such as corticosteroids.

*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.

Highlights

Key Questions Answered

- Future growth in the viscosupplementation market lies in the one-injection segment. What are the current adoption trends in Brazil? How will one-injection segment drive the market revenue growth in the upcoming years?
- Reimbursement is the single greatest barrier to the market growth for viscosupplementation procedures. How does the current payer mix look like in Brazil?
- In recent years, there has been an expansion in the use of intra-articular HA viscosupplementation for treating OA at hips, shoulders, and other small joints. What are the current adoption trends in Brazil?
- Because the most prevalent treatment regimen varies from region to region, the competitive landscape in the viscosupplementation space can be quite different across the geographies covered in this report. Who are the leading players in the viscosupplementation market in Brazil?

Reasons to buy

- “What Do Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table Of Contents

Viscosupplementation - South America Analysis and Market Forecasts
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Treatment Modalities Overview
3.1 Treatment Paradigm
3.1.1 Physical Therapies
3.1.2 Medications
3.1.3 Hyaluronic Acid Viscosupplementation
3.1.4 Surgical Intervention
4 Industry Overview
4.1 Procedural Trends
4.2 Market Access
4.3 Reimbursement
4.4 Mergers and Acquisitions/Key Partnerships
4.4.1 Meda AB Acquires Rottapharm|Medaus for $3.1 Billion (October 2014)
4.4.2 Founders of Anteis Establish Aptissen (March 2014)
4.4.3 Bioventus Acquires Durolane Assets from Galderma (February 2014)
4.4.4 Zimmer to Combine with Biomet in a Transaction Valued at $13.35 Billion (April 2014)
4.4.5 Johnson and Johnson Acquires Synthes for $19.7 Billion (June 2012)
5 Market Drivers, Opportunities, and Barriers
5.1 Driver: Rising Prevalence of OA
5.2 Driver: Multimodal Treatment Paradigm for OA
5.3 Driver: Viscosupplementation Delays Total Knee Replacement
5.4 Driver: Side Effects of NSAIDs, Corticosteroids, and Narcotics
5.5 Driver: Direct-To-Consumer Marketing
5.6 Opportunity: Expanding Indications
5.7 Opportunity: New-Generation HA Derivatives
5.8 Opportunity: Increased Use After Arthroscopic Surgeries
5.9 Opportunity: Self-Pay Market
5.10 Opportunity: Emerging Countries
5.11 Barrier: Unfavorable Reimbursement Scenario
5.12 Barrier: Pricing Erosion
5.13 Barrier: Cost-Effective Pharmacological Therapies
5.14 Barrier: Will The Rising Popularity of PRP Injection Impact the Viscosupplementation Market?
5.15 Barrier: Cost-Conscious Patients in Emerging Countries
6 Unmet Needs
6.1 Lack of Consensus on Clinical Efficacy of Viscosupplementation in Knee OA
6.2 Insufficient Evidence to Prove the Clinical Efficacy of Viscosupplementation in Other Joints
6.3 Better Understanding of the Basic Science
6.4 Ultrasound-Guided Injection
7 Competitive Assessment
7.1 Major Viscosupplementation Products
7.1.1 Adant
7.1.2 Arthrum
7.1.3 Curavisc
7.1.4 Durolane
7.1.5 Euflexxa
7.1.6 Fermathron
7.1.7 Gel-One
7.1.8 Go-On
7.1.9 Hyalgan
7.1.10 Hyalubrix and HyalOne
7.1.11 Jonexa
7.1.12 NeoVisc
7.1.13 Orthovisc and Monovisc
7.1.14 Ostenil
7.1.15 Recosyn
7.1.16 RenehaVis
7.1.17 Supartz/ARTZ
7.1.18 Suplasyn
7.1.19 Suvenyl
7.1.20 Synocrom
7.1.21 Synolis V-A
7.1.22 Synovial
7.1.23 Synvisc and Synvisc-One
7.2 Other Viscosupplementation Products
8 Pipeline Products
8.1 Overview
8.2 Gel-Syn (IBSA Institut Biochimique S.A.)
8.3 Cingal (Anika Therapeutics)
8.4 Hydros-TA (Carbylan Therapeutics)
8.5 Additional Indication for Synvisc-One (Sanofi)
8.6 Hymovis (Fidia Farmaceutici S.p.A.)
8.7 HA-NSAID Conjugates (Seikagaku Corporation)
8.8 Additional Indication for Supartz/ARTZ (Seikagaku Corporation)
8.9 Clodronate-HA Conjugates (Abiogen Pharma)
9 Current and Future Players
9.1 Trends in Corporate Strategy
9.2 Major Manufacturers
9.2.1 Anika Therapeutics
9.2.2 Chugai Pharmaceutical
9.2.3 Ferring Pharmaceuticals
9.2.4 Fidia Farmaceutici S.p.A.
9.2.5 Meda AB
9.2.6 Sanofi
9.2.7 Seikagaku Corporation
9.3 Major Marketing Partners
9.3.1 Bioventus
9.3.2 DePuy Synthes
9.3.3 Zimmer-Biomet
10 Market Outlook
10.1 Market Share Analysis by Country
10.2 Brazil
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Report Methodology
11.3.1 Overview
11.3.2 Coverage
11.3.3 Secondary Research
11.3.4 Forecasting Methodology
11.3.5 Primary Research — Key Opinion Leader Interviews
11.3.6 Expert Panel Validation
11.4 Physicians and Specialists Included in This Study
11.5 About the Authors
11.5.1 Analysts
11.5.2 Jim Coutcher, MS, Global Head of Healthcare
11.6 About MediPoint
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer

1.1 List of Tables
Table 1: Brazil Procedure Trends for Viscosupplementation, by Joint Type, 2012-2021
Table 2: Brazil Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
Table 3: Potential Clinical Benefits of HA-NSAIDs Conjugates
Table 4: Current CPGs on the Use of Viscosupplementation in Joints Other Than the Knee
Table 5: Product Profile - Adant
Table 6: Product Profile - Arthrum
Table 7: Product Profile - Curavisc
Table 8: Product Profile - Durolane
Table 9: Product Profile - Euflexxa
Table 10: Product Profile - Fermathron
Table 11: Product Profile - Gel-One
Table 12: Product Profile - Go-On
Table 13: Product Profile - Hyalgan
Table 14: Product Profile - Hyalubrix and HyalOne
Table 15: Product Profile - Jonexa
Table 16: Product Profile - NeoVisc
Table 17: Product Profile - Orthovisc and Monovisc
Table 18: Product Profile - Ostenil
Table 19: Product Profile - Recosyn
Table 20: Product Profile - RenehaVis
Table 21: Product Profile - Supartz/ARTZ
Table 22: Product Profile - Suplasyn
Table 23: Product Profile - Suvenyl
Table 24: Product Profile - Synocrom
Table 25: Product Profile - Synolis V-A
Table 26: Product Profile - Synovial
Table 27: Product Profile - Synvisc and Synvisc-One
Table 28: Other Viscosupplementation Products in the Global Market, 2015
Table 29: Major Pipeline Products in the Viscosupplementation Market, 2015
Table 30: Company Profile - Anika Therapeutics
Table 31: Anika Therapeutics' Viscosupplementation Portfolio Assessment, 2015
Table 32: SWOT Analysis - Anika Therapeutics
Table 33: Company Profile - Chugai Pharmaceutical
Table 34: Chugai Pharmaceutical's Viscosupplementation Portfolio Assessment, 2015
Table 35: SWOT Analysis - Chugai Pharmaceutical
Table 36: Company Profile - Ferring Pharmaceuticals
Table 37: Ferring Pharmaceutical's Viscosupplementation Portfolio Assessment, 2015
Table 38: SWOT Analysis - Ferring Pharmaceuticals
Table 39: Company Profile - Fidia Farmaceutici S.p.A.
Table 40: Fidia Farmaceutici S.p.A.'s Viscosupplementation Portfolio Assessment, 2015
Table 41: SWOT Analysis - Fidia Farmaceutici S.p.A.
Table 42: Company Profile - Meda AB
Table 43: Meda AB's Viscosupplementation Portfolio Assessment, 2015
Table 44: SWOT Analysis - Meda AB
Table 45: Company Profile - Sanofi
Table 46: Sanofi's Viscosupplementation Portfolio Assessment, 2015
Table 47: SWOT Analysis - Sanofi
Table 48: Company Profile - Seikagaku Corporation
Table 49: Seikagaku Corporation's Viscosupplementation Portfolio Assessment, 2015
Table 50: SWOT Analysis - Seikagaku Corporation
Table 51: Company Profile - Bioventus
Table 52: Bioventus' Viscosupplementation Portfolio Assessment, 2015
Table 53: SWOT Analysis - Bioventus
Table 54: Company Profile - DePuy Synthes
Table 55: DePuy Synthes' Viscosupplementation Portfolio Assessment, 2015
Table 56: SWOT Analysis - DePuy Synthes
Table 57: Company Profile - Zimmer-Biomet
Table 58: Zimmer-Biomet's Viscosupplementation Portfolio Assessment, 2015
Table 59: SWOT Analysis - Zimmer-Biomet
Table 60: Brazil Viscosupplementation Market Revenue ($m), 2012-2021

1.2 List of Figures
Figure 1: Brazil Procedure Trends for Viscosupplementation, by Joint Type, 2014
Figure 2: Brazil Adoption Trend for Viscosupplementation, by Treatment Regimen, 2014
Figure 3: Brazil Procedure Trends for Viscosupplementation, by Treatment Regimen, 2012-2021
Figure 4: Payer Mix for Viscosupplementation in Brazil, 2014
Figure 5: Brazil Viscosupplementation Market Share, by Product, 2014
Figure 6: Brazil Viscosupplementation Market Revenue ($m), 2012-2021
Figure 7: Brazil Viscosupplementation Market Revenue Distribution, 2014 and 2021
Figure 8: Breakdown of Physician Survey Participants by Geography (N=61)
Figure 9: Breakdown of Other Primary Research Participants by Geography (N=50)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.